Posted by Michael Wonder on 29 Oct 2019
Terns Pharmaceuticals receives fast track designation from the FDA for TERN-101, an FXR agonist for the treatment of NASH
29 October 2019 - Terns Pharmaceuticals today announced that TERN-101, an investigational farnesoid X receptor (FXR) agonist, has been granted fast track designation by the U.S. FDA for the treatment of NASH.
TERN-101 and TERN-201, Terns’ semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are both in development for the treatment of NASH and were initially discovered and developed by Eli Lilly and Company. Terns signed a global, exclusive license agreement with Eli Lilly in 2018 to develop, manufacture, and commercialize TERN-101 and TERN-201.
